Commentary on Harun et al.: The use of historical controls in randomized clinical trials

Harun N Gupta N McCormack FX , et al. Dynamic use of historical controls in clinical trials for rare disease research: a re-evaluation of the MILES trial. Clin Trials 2023.

Carlin BP Nollevaux F . Bayesian complex innovative trial designs (CIDs) and their use in drug development for rare disease. J Clin Pharmacol 2022; 62(suppl 2): S56–S71.

Kidwell KM Roychoudhury S Wendelberger B , et al. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet J Rare Dis 2022; 17: 186.

Gehan EA Freireich EJ . Non-randomized controls in cancer clinical trials. N Engl J Med 1974; 290: 198–203.

Blum RL Wiederhold G . Inferring knowledge from clinical data banks utilizing techniques from artificial intelligence. In: Orthner FH (ed.) Symposium on computer applications in medical care. New York: IEEE, 1978, pp. 303–307.

Byar DP . Why data bases should not replace randomized clinical trials. Biometrics 1980; 36: 337–342.

Pocock SJ . The combination of randomized and historical controls in clinical trials. J Chronic Dis 1976; 29(3): 175–188.

Freidlin B Korn EL . Augmenting randomized clinical trial data with historical control data: precision medicine applications. JNCI 2023; 115: 14–20.

Roig MB König F Meyer E , et al. Commentary: two approaches to analyze platform trials incorporating non-concurrent controls with a common assumption. Clin Trials 2022; 19(5): 502–503.

US Food Drug Administration. Complex innovative trial design meeting program, https://www.fda.gov/drugs/development-resources/complex-innovative-trial-design-meeting-program (2023, accessed 15 January 2023).

Price D Scott J . The US Food and Drug Administration’s complex innovative trial design pilot meeting program: progress to date. Clin Trials 2021; 18: 706–710.

Yin PT Desmond J Day J . Sharing historical trial data to accelerate clinical development. Clin Pharmacol Ther 2019; 106(6): 1177–1178.